Monopotassium Phosphate
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Monopotassium Phosphate
- Pharmacist Assessment Report
- Monopotassium Phosphate: From an Electrolyte Replacement Product to Renal Tubular Acidosis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Monopotassium Phosphate: From an Electrolyte Replacement Product to Renal Tubular Acidosis
One-Sentence Summary
Monopotassium phosphate is a potassium and phosphate salt marketed in Canada in injectable and multi-electrolyte products, but the data compiled for this report contain no approved-indication text. The TxGNN model predicts it may be useful for renal tubular acidosis, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction rests on the model alone and should be treated as a research question, not a treatment recommendation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Canadian licence data (the products are potassium phosphate and electrolyte preparations) |
| Predicted New Indication | Renal tubular acidosis |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 5 of 5) |
| Number of DINs | 5 (marketed: 5) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, monopotassium phosphate supplies potassium and phosphate, and it is used in electrolyte replacement products. Mechanistically, it may be applicable to some renal acid-base disorders.
Urinary phosphate acts as a urinary buffer (titratable acid), and phosphate salts are sometimes used in renal acid-base disorders. Potassium repletion could also matter in distal renal tubular acidosis with low potassium. These points make the prediction a plausible hypothesis, but only that.
There is an important caveat. Monopotassium phosphate is acidifying, not alkalinizing, so it could be counterproductive in patients who are already acidotic. No trial or literature data were found to resolve this question.
Other predicted indications are listed below for context. All lack trial or literature support.
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Assessment |
|---|---|---|---|---|
| 2 | Acute urate nephropathy | 0.9980 | L5 | No clear rationale; phosphate load and urinary acidification may cause harm |
| 3 | Dyspepsia | 0.9974 | L5 | No known mechanism; likely a TxGNN model (deep learning) artifact, and oral salts commonly irritate the gut |
| 4 | Potassium deficiency disease | 0.9973 | L5 | Direct rationale, especially with low phosphate as well; potassium chloride is usually first-line |
| 5 | Nephrolithiasis | 0.9957 | L5 | Depends on stone type; may help or harm |
| 6 | Calcium-alkali syndrome | 0.9933 | L5 | Phosphate loading risks calcification and worse kidney function |
| 7 | Primary bone dysplasia with defective mineralization | 0.9902 | L5 | Plausible for phosphate-wasting rickets; the category is broad, and the potassium load matters |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00711306 | Potassium Phosphate Monobasic Injection | Not specified | Not specified |
| 02139545 | Potassium Phosphates Injection, USP | Not specified | Not specified |
| 00804789 | Potassium Phosphates | Not specified | Not specified |
| 00800007 | Tis-U-Sol Solution | Not specified | Not specified |
| 01931679 | Isolyte S pH 7.4 (Multi-Electrolyte Injection) | Not specified | Not specified |
All five licences are valid authorizations.
Safety Considerations
- Contraindications suggested by the knowledge graph (these come from drug-disease links in the model’s knowledge graph, not from label text): liver failure, congestive heart failure, cirrhosis of the liver, anuria, hypercalcaemia, nephrocalcinosis, phosphorus metabolism disease, hyperphosphataemia, hypoaldosteronism, and myotonia congenita.
- Drug Interactions (19 found): 16 are minor and 3 are moderate.
- Moderate: ibuprofen, flurbiprofen, diclofenac.
- Minor: various insulin products, ephedrine, and pseudoephedrine.
- Monitoring: if this drug were pursued, serum potassium, phosphate, calcium, and renal function would need monitoring.
Please also refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score, with no clinical trials or publications. The drug’s acidifying nature may work against its use in renal tubular acidosis, and the knowledge graph flags several relevant renal and electrolyte contraindications.
To proceed, the following is needed:
- Package insert warnings and contraindications from Health Canada, which are required before any safety screening
- Approved indication text and dosage forms for the Canadian products
- Mechanism of action data
- A literature and trial search specific to phosphate or potassium phosphate in renal tubular acidosis
- Clarification of whether the acidifying effect is compatible with the target patients
- If the question is pursued, consider potassium deficiency disease (potassium and phosphate co-depletion) as a better-grounded direction than renal tubular acidosis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.